To add a bio or update investment portfolio click update information.
Oshen Bio
Investment Portfolio
Healome Therapeutics
7 Jul 2026
Healome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
Healome Therapeutics is a University of Birmingham spinout developing an eye-drop matrix technology that extends the residence time of therapeutics on the ocular surface. The platform is designed for use in dry eye disease, ocular surface inflammation, corneal injury and rare diseases causing severe ocular surface damage.
Scarlet Therapeutics
11 May 2026
Scarlet Therapeutics raises a £3.2m seed round led by Eos Advisory to advance red blood cell treatments for diseases
Scarlet Therapeutics develops engineered red blood cells designed to treat metabolic diseases and address shortages in rare blood supplies. Scarlet Therapeutics uses synthetic biology and proprietary cell line technology to create lab-grown red blood cells that can be manufactured at scale for therapeutic and transfusion use.
Oshen Bio
- 2(12 months)
- oshenbio.com
- Update Information
More venture news
- 8 Jul 2026
HIVEHIVE lands £11m in a seed round led by SuperSeed to make industrial machines autonomous with silicon brain
SeedIndustrial - 9 Jul 2026
MarkerMarker raises a £10m seed round led by Index Ventures to support writers with AI word processor
SeedMedia & Entertainment - 8 Jul 2026
NexcadeNexcade secures a £4.5m seed round led by Project A Ventures to expand its AI agent platform for freight forwarding
SeedSupply Chain
